SB 5361
SignedSenate
ASAM 4 treatment criteria
Delaying the use of the ASAM 4 criteria, treatment criteria for addictive, substance related, and co-occurring conditions.
How does a bill become law?
- Introduced: The bill is filed and assigned a number.
- Committee: A subject-matter committee holds hearings, takes public testimony, and decides whether to advance the bill.
- Floor Vote: The full chamber (House or Senate) debates and votes on the bill.
- Opposite Chamber: The bill repeats the committee and floor vote process in the other chamber.
- Governor: The Governor reviews the bill and decides whether to sign or veto it.
- Signed: The bill has been signed into law.
AI Analysis
This bill delays the mandatory use of the updated ASAM Criteria—clinical guidelines for treating addiction and co-occurring disorders—by two years, moving the deadline from January 1, 2026, to January 1, 2028. It also requires state agencies to jointly review and approve the adoption of future updates before they take effect.
- Delays the required use of the updated ASAM Criteria (4th edition) for substance use and co-occurring disorder treatment by Medicaid managed care organizations and insurance carriers from January 1, 2026, to January 1, 2028.
- Requires the Washington State Health Care Authority and the Office of the Insurance Commissioner to jointly decide whether to adopt the updated ASAM Criteria and, if so, set the start date—up to the new deadline of January 1, 2028.
- Mandates that both agencies post their decision on their official websites, ensuring public transparency about when and if the new criteria will be used.
- Applies to all versions of the ASAM Criteria—including those for adolescents and transition-age youth—when they are updated by the American Society of Addiction Medicine.
Who is affected
- Individuals with substance use or co-occurring disorders — People receiving or seeking treatment for substance use disorders or co-occurring mental health and substance use conditions through Medicaid (Apple Health) or private insurance plans covered by the bill.
- Health care providers and treatment programs — Must update their clinical practices and documentation to meet new treatment criteria standards when they take effect.
- Medicaid managed care organizations and health insurance carriers — Must adjust their coverage policies, billing systems, and provider contracts to align with the updated criteria.
- Washington State Health Care Authority and Office of the Insurance Commissioner — Responsible for reviewing the new criteria and deciding whether and when to adopt them, then publicly sharing that decision.
Pro/Con Analysis
Stronger case for concerns
Potential Benefits (2)
Provides time for providers and insurers to prepare for implementation, potentially reducing administrative burden and system disruption during rollout—though this benefit is offset by delayed clinical improvements.
Local GovernmentRef: Sec. 1 & 2 (joint agency review and approval process)Mandates transparency by requiring agencies to publicly post decisions on ASAM adoption, improving accountability and stakeholder awareness—though this is a procedural improvement with limited direct impact on outcomes.
transparencyRef: Sec. 1 & 2 (public posting of agency decisions)
Potential Concerns (3)
Delays adoption of evidence-based clinical guidelines for substance use and co-occurring disorder treatment, potentially prolonging inconsistent or substandard care for individuals with addiction, especially those on Medicaid, as providers and insurers retain flexibility to use outdated standards until 2028.
HealthcarePeopleRef: Sec. 1 & 2 (delaying ASAM 4 criteria implementation to Jan. 1, 2028)Introduces bureaucratic delay and uncertainty by requiring two state agencies to jointly evaluate and approve future ASAM updates, which may slow or prevent adoption of improved clinical standards—even if clinically superior—due to interagency coordination challenges or political considerations.
HealthcarePeopleRef: Sec. 1 & 2 (joint agency review and approval process)Postponing updated clinical criteria may reduce the likelihood of early identification and standardized treatment of co-occurring disorders, potentially increasing risk of untreated crises, ER visits, and incarceration—especially among vulnerable populations like youth and people experiencing homelessness.
Public SafetyLean peopleRef: Sec. 1 & 2 (delaying implementation to 2028)
Who Is Most Affected
Individuals with substance use or co-occurring disorders—especially low-income, Medicaid-enrolled, or youth—face longer delays in receiving standardized, evidence-based care, increasing risk of relapse, hospitalization, or incarceration.
Providers (especially community mental health and addiction clinics) gain extra time to adapt systems, but may face confusion or inconsistency if some insurers adopt ASAM 4 earlier than others, complicating billing and documentation.
Insurers and Medicaid MCOs benefit from extended time to adjust systems and avoid upfront costs, but may face reputational or regulatory risk if delayed adoption is perceived as resisting clinical progress.
State agencies gain flexibility and time to coordinate, but their joint decision-making authority introduces political risk—if they decline to adopt ASAM 4, they may face criticism from clinicians and advocates.